{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Sheet1"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":8,"n_cols":5,"rows_kept":8,"flags":["formulas_cached_only"]}
["Table 3 The top 3 enriched KEGG pathways of DEGs associated with CRC"]
[null,"Category","Term","Count","FDR"]
["Upregulated ","KEGG_PATHWAY","Rheumatoid arthritis",15,{"v":4.86e-08,"d":"4.86E-08"}]
[null,"KEGG_PATHWAY","IL-17 signaling pathway",15,{"v":4.86e-08,"d":"4.86E-08"}]
[null,"KEGG_PATHWAY","Cytokine-cytokine receptor interaction",20,{"v":3.49e-05,"d":"3.49E-05"}]
["Downregulated ","KEGG_PATHWAY","Metabolic pathways",83,{"v":3.64e-07,"d":"3.64E-07"}]
[null,"KEGG_PATHWAY","Drug metabolism - cytochrome P450",15,{"v":1.38e-06,"d":"1.38E-06"}]
[null,"KEGG_PATHWAY","Bile secretion",16,{"v":2.09e-06,"d":"2.09E-06"}]